• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

PathAI’s AISight Dx Receives CE Mark for Primary Diagnosis

by Fred Pennic 08/29/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
PathAI Lands $60M to Accelerate AI-Powered Pathology Platform

What You Should Know: 

– PathAI, a pioneer in AI-powered digital pathology, has achieved a significant milestone with the CE mark certification of its AISight Dx Image Management System (IMS) for primary diagnosis. 

– The certification paves the way for PathAI’s expansion into the European diagnostic pathology market, offering pathologists a powerful tool to enhance their interpretations and improve laboratory efficiency.

AISight Dx: A Comprehensive Digital Pathology Platform

AISight Dx is a meticulously designed platform that streamlines end-to-end digital pathology workflows. Developed with input from over 200 pathologists, AISight Dx offers a range of features, including:

  • Caseload balancing and assignment: Optimizes workload distribution among pathologists.
  • Image ingestion: Efficiently imports and manages digital pathology images.
  • Image viewing: Provides advanced tools for viewing and analyzing images.
  • Collaboration tools: Facilitates collaboration among pathologists and other healthcare professionals.
  • Image and case management: Streamlines the management of digital pathology cases.

Enhanced Workflow Efficiency and Integration

AISight Dx seamlessly integrates with laboratory information systems through AISight Link, further enhancing workflow efficiency. This integration enables smooth data transfer and reduces manual tasks, allowing pathologists to focus on their core responsibilities.

Benefits for Anatomic Pathology Laboratories

AISight Dx offers numerous benefits for anatomic pathology laboratories of all sizes and specialties:

  • Improved accuracy: AI-powered tools can help enhance diagnostic accuracy and consistency.
  • Increased efficiency: Streamlined workflows and automated tasks can improve laboratory productivity.
  • Enhanced collaboration: Collaborative features facilitate communication and knowledge sharing among pathologists.
  • Scalability: AISight Dx can handle large volumes of data and adapt to the needs of growing laboratories.

“The IVDR certification demonstrates PathAI’s unwavering commitment to providing safe, effective, and high-quality diagnostic solutions,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “It not only confirms the compliance of our AISight platform with the latest European regulations but also strengthens our ability to assist pathologists in delivering accurate diagnoses and improving patient outcomes across Europe.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Digital Pathology, PathAI

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |